MKMehul Kaliya

Mehul Kaliya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehul Kaliya has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Public Health in the Digital Era: A Narrative Review of Technology-driven Interventions and Programmatic Advances in India

    by Mittal Rathod, Mehul Kaliya

    Digital technologies are increasingly integral to public health systems, offering opportunities to improve disease surveillance, service delivery, efficiency and equity. In India, multiple government-led digital platforms have been implemented across public health programmes; however, consolidated evidence on their scope, effectiveness and implementation challenges remains limited. The manuscript was prepared in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) guidelines. This narrative review aimed to examine technology-driven public health interventions implemented in India, focusing on government-supported digital platforms excluding artificial intelligence-based tools, and summarised their applications, achievements and limitations. A narrative review using a structured search strategy was conducted across PubMed, Google Scholar, Scopus, ResearchGate and official portals of the Ministry of Health and Family Welfare, National Health Mission and WHO-SEARO. English-language literature published between January 2005 and June 2025 was included. Eligible source findings were thematically synthesised across major public health domains. Thirty-five eligible studies and national programme documents were included. Digital platforms such as Integrated Disease Surveillance Programme and Integrated Health Information Platform strengthened disease surveillance through real-time reporting and outbreak analytics. Maternal and child health tools (Mother and Child Tracking System, ANMOL, and Kilkari) improved beneficiary tracking, antenatal follow-up and health education. Immunisation systems (Electronic Vaccine Intelligence Network, CoWIN/U-WIN) enhanced vaccine logistics and coverage. Platforms for non-communicable diseases and telemedicine supported continuity of care and expanded access to specialist services. Key challenges included digital literacy gaps, connectivity constraints, interoperability issues, workforce burden and data governance concerns. Digital platforms have strengthened specific public health functions in India, but have not achieved uniform system-wide transformation. Addressing interoperability, evaluation frameworks, equity and governance is essential to maximise their public health impact.

  • Integrated coagulation, platelet, and UACR profiling in type 2 diabetes microvascular complications: a western India study

    by Parth R. Goswami, Mehul Kaliya, Garima Anandani, Amit D. Sonagra, Kedar Nemivant, Gyanendra Singh, Sagar Dholariya, Vaishali Bhankhodia

    1. Diabetes mellitus (DM) is a significant global health issue that afflicts over 537 million adults worldwide, especially type 2 diabetes mellitus (T2DM), which accounts 90% of DM cases [1,2]. Bey...

  • Urinary adiponectin as a non-invasive biomarker of renal impairment in type 2 diabetes mellitus: evidence from a cross-sectional study

    by Gyanendra Singh, Sagar Dholariya, Mehul Kaliya, Anjali Modi, Amit Sonagra, Deepak Parchwani

    1. Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease and end-stage renal disease worldwide, and its burden is particularly high in India, where pooled estimates suggest tha...

  • Open Access

    Financial Burden of Drug-sensitive Tuberculosis in India: A Systematic Review and Meta-analysis

    by Subba Krishna Nagaraj, K. S. Aviraj, Renu Agrawal, Mittal Rathod, Mehul Kaliya

    Introduction: Tuberculosis (TB) poses a significant public health and economic burden in India, with out-of-pocket expenditure (OOPE) often leading to financial distress. This study reviews and meta-analyses costs associated with drug-sensitive TB care in India. Methods: Relevant studies from PubMed, Scopus, OpenAlex, CrossRef and Semantic Scholar were analysed. A random-effects meta-analysis estimated mean costs, including direct medical, direct non-medical, indirect medical, diagnostic and treatment expenses. Results: Analysing 18 studies, the overall mean cost per TB patient was ₹18,961 (95% confidence interval: ₹12,093–₹25,829), with direct medical costs at ₹7305, direct non-medical costs at ₹2346, indirect medical costs at ₹10,602, diagnostic costs at ₹10,028 and treatment costs at ₹12,999. Conclusion: TB care imposes a heavy financial burden on Indian households. Reducing OOPE through targeted interventions, strengthened social protection and expanded free services is essential to alleviate this hardship.


  • Stage-specific association of urinary C-megalin with diabetic kidney disease: a cross-sectional study in type 2 diabetes

    by Sagar Dholariya, Gyanendra Singh, Mehul Kaliya, Ragini Singh, Amit Sonagra, Deepak Parchwani

    This study aimed to evaluate urinary C-megalin in relation to disease staging and diagnostic accuracy in Indian patients with type 2 diabetes mellitus (T2DM). In this cross-sectional study, 325 participants were classified into No-DKD, early-DKD, and late-DKD based on kidney disease improving global outcomes (KDIGO) criteria. Urinary C-megalin was quantified by enzyme-linked immunosorbent assay (ELISA) as absolute and creatinine-normalized values. Group comparisons, correlation analyses, and multinomial logistic regression were performed to assess associations with disease stage. Creatinine-normalized C-megalin excretion was higher in early-DKD compared with No-DKD (median 125.0 vs. 92.0 ng/mg Cr; p = 0.02) and independently associated with early disease [odds ratio (OR) = 1.26, 95% confidence interval (CI): 1.03-1.55; p = 0.02). In late-DKD, absolute C-megalin levels were significantly associated with disease status (OR = 1.23, 95% CI: 1.02-1.48; p = 0.03), while normalized values lost significance. Diagnostic evaluation showed moderate accuracy for detecting early-DKD [area under curve (AUC): 0.69, 95% CI: 0.62-0.76, p = 0.001). Urinary C-megalin demonstrates stage-dependent diagnostic behavior in DKD, suggesting potential as a complementary marker for early tubular injury and advanced disease in high-risk diabetic populations.

  • Unveiling the utility of artificial intelligence for prediction, diagnosis, and progression of diabetic kidney disease: an evidence-based systematic review and meta-analysis

    by Sagar Dholariya, Siddhartha Dutta, Amit Sonagra, Mehul Kaliya, Ragini Singh, Deepak Parchwani, Anita Motiani

    The purpose of this study was to conduct a systematic investigation of the potential of artificial intelligence (AI) models in the prediction, detection of diagnostic biomarkers, and progression of diabetic kidney disease (DKD). In addition, we compared the performance of non-logistic regression (LR) machine learning (ML) models to conventional LR prediction models. Until January 30, 2024, a comprehensive literature review was conducted by investigating databases such as Medline (via PubMed) and Cochrane. Research that is inclusive of AI or ML models for the prediction, diagnosis, and progression of DKD was incorporated. The area under the Receiver Operating Characteristic Curve (AUROC) served as the principal outcome metric for assessing model performance. A meta-analysis was performed utilizing MedCalc statistical software to calculate pooled AUROC and assess the performance differences between LR and non-LR models. A total of 57 studies were included in the meta-analysis. The pooled AUROC of AI or ML model was 0.84 (95% CI = 0.81-0.86, p < 0.0001) for analyzing prediction of DKD, 0.88 (95%CI = 0.84-0.92, p < 0.0001) for detecting diagnostic biomarkers, and 0.80 (95% CI = 0.77-0.82, p < 0.0001) for analyzing progression of DKD. The pooled AUROC of LR and non-LR ML models exhibited no significant differences across all categories (p > 0.05), except for the random forest (RF) model, which displayed a statistically significant increase in predictive accuracy compared to LR for DKD occurrence (p < 0.04). ML models showed solid DKD prediction effectiveness, with pooled AUROC values over 0.8, suggesting good performance. These data demonstrated that non-LR and LR models perform similarly in overall CKD management, but the RF model outperforms the LR model, particularly in predicting the occurrence of DKD. These findings highlight the promise of AI technologies for better DKD management. To improve model reliability, future study should include extended follow-up periods as well as external validation.


  • Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis

    by Sagar Dholariya, Siddhartha Dutta, Ragini Singh, Deepak Parchwani, Amit Sonagra, Mehul Kaliya

    This study assessed the clinical safety and efficacy of bexagliflozin, a sodium-glucose cotransporter 2(SGLT2) inhibitor, in managing glycemia among patients with type 2 diabetes mellitus (T2DM). We examined RCTs with T2DM comparing the clinical effectiveness and safety of 20 mg once daily oral dose of bexagliflozin with placebo for managing glycemia till 28 May 2023, published on databases like ClinicalTrials.gov, PubMed, Embase, and Cochrane Library. Furthermore, reduction of body weight and systolic blood pressure (SBP) and the percentage of individuals who achieved glycated hemoglobin (HbA1c) of < 7% from baseline were also evaluated. The Review Manager 5 was utilized to investigate the retrieved data. We involved eight RCTs. Bexagliflozin was significantly superior in reducing HbA1c[least squares mean difference(LSMD) = -0.45,95% confidence interval (CI =-0.55 to -0.34,p < 0.00001], fasting plasma sugar(FPG)[LSMD= -1.37, 95%CI =-1.73 to -1.00, p < 0.00001], body weight (LSMD= -1.77, 95%CI =-2.44 to-1.10, p < 0.00001), and SBP(LSMD= -4.11,95%CI = -6.18 to -2.03,p = 0.0001) in comparison to placebo. The safety outcomes of bexagliflozin were consistent with the placebo arm. This study concluded that bexagliflozin seems to be a promising oral anti-diabetic drug for enhancing glycemic management in adult patients with T2DM.